This report was first published by Endpoints News. To see the original version, click here
Parabilis Medicines, the decade-old and well-funded “undruggable” biotech out of Greg Verdine’s Harvard lab, seeks to become the 12th drug developer to conduct an initial public offering this year.
The biotech submitted its pitch for a Nasdaq listing on Tuesday evening, just a day after disclosing a biobucks-rich pact with Regeneron that is worth more than $2 billion across five initial targets.
您已阅读11%（487字），剩余89%（3920字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。